Impact of Brokerage Rating on Depomed, Inc.(DEPO)

Many Depomed, Inc.(DEPO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Depomed Inc was Downgraded by Mizuho on Feb 14, 2017 to Neutral, Lowers Price Target to $ 17 from a previous price target of $24 .Depomed Inc was Downgraded by Piper Jaffray to Underweight on Dec 12, 2016.

Company has reported several Insider transactions to the SEC, on Nov 15, 2016, August J Moretti (Chief Financial Officer & SVP) sold 5,000 shares at 20.84 per share price.On Sep 22, 2016, Thadd M Vargas (Senior VP, BD) sold 11,250 shares at 25.00 per share price.

Depomed Inc Last issued its quarterly earnings results on Nov 7, 2016. The company reported $0.28 EPS for the quarter, missing the analyst consensus estimate by $ -0.08. Analyst had a consensus of $0.36. The company had revenue of $110.50 million for the quarter, compared to analysts expectations of $126.82 million. The companys revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.33 EPS.

Depomed, Inc. (NASDAQ:DEPO): 10 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $22.4 in Depomed, Inc. (NASDAQ:DEPO). However, the stock price could fluctuate by $ 4.72 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $27 price target with the lower price estimate is calculated at $14

Depomed, Inc. (NASDAQ:DEPO) witnessed a decline in the market cap on Tuesday as its shares dropped 1.88% or 0.32 points. After the session commenced at $16.44, the stock reached the higher end at $16.8 while it hit a low of $16.05. With the volume soaring to 2,199,769 shares, the last trade was called at $16.68. The company has a 52-week high of $27.0199. The company has a market cap of $1,027 million and there are 61,580,665 shares in outstanding. The 52-week low of the share price is $12.25.

Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin XR extended-release tablets have been approved by the FDA for the once-daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once-daily Glumetza has been approved for use in adults with type two diabetes and is currently being marketed in the United States and Canada. The company is currently evaluating Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, and menopausal hot flashes.


For any feedback and suggestions contact author at

Add Comment